NCT01337089
Long Term Safety of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain
Chorzy
kontynuacja poprzedniego badania
Faza badania
III
Sponsor badania
GW Pharmaceuticals
Termin
-
Linki
Dane kontaktowe
Bielsko-Biała; Gliwice; Poznań; Warszawa